Mass Spectrometry Market Size to Reach USD 12.3 Billion By 2032, at 8.8% CAGR: Dimension Market Research
April 24, 2024 12:40 ET
|
Dimension Market Research
New York, April 24, 2024 (GLOBE NEWSWIRE) -- Overview The Global Mass Spectrometry Market was valued of USD 5.7 billion in 2023 which is further expected to reach USD 12.3 billion by the year...
Zylö announces the creation and spinout of Atticus Pharma Inc.
April 17, 2024 08:00 ET
|
Zylö Therapeutics
Atticus to focus on biopharma applications of the innovative ‘Powered by Z-pod®’ topical-delivery platform GREENVILLE, SC, April 17, 2024 (GLOBE NEWSWIRE) -- Zylö recently effected a spinout of...
Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence
April 17, 2024 08:00 ET
|
Bionano Genomics
Bionano and Diagens form strategic partnership to commercialize OGM plus AI cytogenetic analysis for reproductive health in China.
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
April 17, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
XPENG Publishes 2023 Environmental, Social and Governance Report
April 17, 2024 06:35 ET
|
XPeng Inc.
XPENG published 2023 Environmental, Social and Governance Report
XPENG and the Volkswagen Group Announce Entry into the Framework Agreement on E/E Architecture Technical Collaboration
April 17, 2024 04:19 ET
|
XPeng Inc.
XPENG and Volkswagen Group Announce Entry into Framework Agreement on E/E Architecture Technical Collaboration
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market
April 16, 2024 14:06 ET
|
Spherix Global Insights
EXTON, PA, April 16, 2024 (GLOBE NEWSWIRE) -- In October of 2023, the US FDA approved Novartis’ intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of psoriatic arthritis (PsA),...
SAB Biotherapeutics Provides SAB-142 Trial Update
April 16, 2024 07:15 ET
|
SAB Biotherapeutics, Inc.
SAB Biotherapeutics provides update on SAB-142 clinical trial for type 1 diabetes
London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami
April 15, 2024 08:00 ET
|
London Research and Pharmaceuticals
London Research & Pharmaceuticals Corp. Presents the Advancement of their Oral Cannabidiol Sulphate Drug Candidate at Epilepsy Therapies Conference
Medicines360 Appoints Erica Rogers to Board of Directors
April 10, 2024 06:00 ET
|
Medicines360
Medicines360, a global mission-driven women's health company, has appointed Erica Rogers to the Board of Directors.